Scandion Oncology ready for phase II with SCO-101 22 november, 2019Scandion Oncology’s candidate SCO-101 is being developed to fight resistance to cancer drugs and is ready to enter phase II clinical trials. Metastatic colorectal cancer patients will be the first to be tested ... LÄS MER!
Scandion Oncology CEO: SCO-101 promises blockbuster potential 21 november, 2019Scandion Oncology’s candidate SCO-101 is being developed to fight resistance to cancer drugs. The novel mechanism of action makes SCO-101 a First-in-Class candidate, something that has not gone unnoticed in the... LÄS MER!
